WallStreetZenWallStreetZen

NASDAQ: VYGR
Voyager Therapeutics Inc Stock

$9.31-0.25 (-2.62%)
Updated Mar 28, 2024
VYGR Price
$9.31
Fair Value Price
$14.92
Market Cap
$505.54M
52 Week Low
$6.06
52 Week High
$14.34
P/E
3.02x
P/B
2.14x
P/S
1.45x
PEG
0.03x
Dividend Yield
N/A
Revenue
$250.01M
Earnings
$132.33M
Gross Margin
100%
Operating Margin
48.81%
Profit Margin
52.9%
Debt to Equity
0.49
Operating Cash Flow
$78M
Beta
1.25
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VYGR Overview

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VYGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VYGR ($9.31) is undervalued by 37.61% relative to our estimate of its Fair Value price of $14.92 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VYGR ($9.31) is significantly undervalued by 37.61% relative to our estimate of its Fair Value price of $14.92 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VYGR ($9.31) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VYGR due diligence checks available for Premium users.

Be the first to know about important VYGR news, forecast changes, insider trades & much more!

VYGR News

Valuation

VYGR fair value

Fair Value of VYGR stock based on Discounted Cash Flow (DCF)
Price
$9.31
Fair Value
$14.92
Undervalued by
37.61%
VYGR ($9.31) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VYGR ($9.31) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VYGR ($9.31) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VYGR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
3.02x
Industry
14.26x
Market
44.51x
VYGR is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VYGR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

VYGR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.14x
Industry
6.21x
VYGR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VYGR price to earnings growth (PEG)

For valuing profitable companies with growth potential
VYGR is good value based... subscribe to Premium to read more.
PEG Value Valuation

VYGR's financial health

Profit margin

Revenue
$90.1M
Net Income
$56.4M
Profit Margin
62.6%
VYGR's Earnings (EBIT) of $122.02M... subscribe to Premium to read more.
Interest Coverage Financials
VYGR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$351.3M
Liabilities
$115.0M
Debt to equity
0.49
VYGR's short-term assets ($319.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYGR's short-term assets ($319.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.8M
Investing
$26.8M
Financing
$460.0k
VYGR's operating cash flow ($77.92M)... subscribe to Premium to read more.
Debt Coverage Financials

VYGR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VYGR$505.54M-2.62%3.02x2.14x
SLDB$502.92M-6.53%-2.76x3.98x
MESO$508.41M+43.55%-5.49x1.00x
REPL$501.54M-0.97%-2.59x1.19x
KALV$500.35M+7.14%-3.79x5.65x

Voyager Therapeutics Stock FAQ

What is Voyager Therapeutics's quote symbol?

(NASDAQ: VYGR) Voyager Therapeutics trades on the NASDAQ under the ticker symbol VYGR. Voyager Therapeutics stock quotes can also be displayed as NASDAQ: VYGR.

If you're new to stock investing, here's how to buy Voyager Therapeutics stock.

What is the 52 week high and low for Voyager Therapeutics (NASDAQ: VYGR)?

(NASDAQ: VYGR) Voyager Therapeutics's 52-week high was $14.34, and its 52-week low was $6.06. It is currently -35.08% from its 52-week high and 53.63% from its 52-week low.

How much is Voyager Therapeutics stock worth today?

(NASDAQ: VYGR) Voyager Therapeutics currently has 54,300,627 outstanding shares. With Voyager Therapeutics stock trading at $9.31 per share, the total value of Voyager Therapeutics stock (market capitalization) is $505.54M.

Voyager Therapeutics stock was originally listed at a price of $17.75 in Nov 11, 2015. If you had invested in Voyager Therapeutics stock at $17.75, your return over the last 8 years would have been -47.55%, for an annualized return of -7.75% (not including any dividends or dividend reinvestments).

How much is Voyager Therapeutics's stock price per share?

(NASDAQ: VYGR) Voyager Therapeutics stock price per share is $9.31 today (as of Mar 28, 2024).

What is Voyager Therapeutics's Market Cap?

(NASDAQ: VYGR) Voyager Therapeutics's market cap is $505.54M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Voyager Therapeutics's market cap is calculated by multiplying VYGR's current stock price of $9.31 by VYGR's total outstanding shares of 54,300,627.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.